The S&P/ASX 200 Index (ASX: XJO) is having a disappointing session on Tuesday. In afternoon trade, the benchmark index is down 1.2% to 9,088.9 points.
Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:
Image source: Getty Images
Capstone Copper Corp (ASX: CSC)
The Capstone Copper share price is down 8% to $13.29. This morning, this copper miner revealed full-year production growth of 22% to 224,764 tonnes with a cash cost of $2.44 per pound. However, it also provided guidance for FY 2026, which revealed that it expects production of just 200,000 to 230,000 tonnes with cash costs of $2.45 to $2.75 per pound. The higher costs are expected to be driven by modest inflation and the impact of lower-grade zones driven by mine sequence at Mantos Blancos and Pinto Valley.
Life360 Inc (ASX: 360)
The Life360 share price is down 10% to $22.10. Investors have been selling this family safety technology company's shares following the release of its full-year results. At one stage today, Life360's shares were up as much as 15% before making a significant U-turn. Interestingly, this is despite Life360 delivering earnings ahead of expectations and reiterating its guidance for FY 2026. However, it is worth noting that the tech sector is a sea of red today.
Neuren Pharmaceuticals Ltd (ASX: NEU)
The Neuren Pharmaceuticals share price is down 7.5% to $12.73. This morning, this pharmaceuticals company confirmed that European regulators have rejected its application for trofinetide for the treatment of Rett syndrome. Its partner, Acadia Pharmaceuticals (NASDAQ: ACAD), commented: "While we are disappointed by the CHMP's recommendation to refuse approval, we continue to be encouraged by the meaningful benefits trofinetide has demonstrated for people living with Rett syndrome. The strong engagement and positive feedback we have seen from patients, caregivers, and clinicians in the Rett community reinforce our belief in the treatment's clinical value. We remain committed to working constructively with EU regulators to explore next steps and to bring this therapy to patients."
St George Mining Ltd (ASX: SGQ)
The St George Mining share price is down 15.5% to 13.5 cents. This is despite the rare earths explorer announcing a substantial increase in the size and quality of the mineral resource estimate at its 100%-owned Araxa Project. Management believes this confirms the tier one status of the rare earths and niobium deposit in the world's premier niobium-producing region. However, it seems that investors were expecting stronger numbers.
